BD (Becton, Dickinson and Company) announced a major partnership with the U.S. government to invest $19 billion in expanding domestic manufacturing of essential medical consumables. This initiative aims to strengthen healthcare supply chains, increase U.S. production capacity by about 5 billion units annually, and ensure 100% domestic production of needles using American steel. The agreement supports the U.S. government's goal to build a more resilient healthcare system and provides tariff relief to secure long-term manufacturing plans. BD's investments will enhance innovation and healthcare infrastructure across multiple U.S. locations, reinforcing its role in critical healthcare supply.
BDX shares trade at USD 182.67 on Pluang, up 1.11% as of Oct 06, 2026 17:51 WIB, reflecting steady investor interest in the company amid its new $19 billion partnership with the U.S. government. The stock’s market cap stands at $49.21 billion, underscoring BD's significant presence in the healthcare sector. This partnership aligns with BD's ongoing role in strengthening healthcare supply chains and expanding manufacturing capacity.
